The Department of Data Science is delighted to announce that Meredith M. Regan, ScD, is promoted to Professor of Medicine as of October 1st.
Dr. Regan is a graduate of Harvard TH Chan School of Public Health and joined our faculty in 2003. In addition to appointments at Dana-Farber and Harvard Medical School, Dr. Regan is Director of the International Breast Cancer Study Group Statistical and Data Management Center, centered at DFCI since 1977. Her research focuses on clinical-translational investigations to inform patient care and treatment selection for breast and genitourinary cancers and on clinical trial endpoints. She co-leads the IBCSG’s SOFT/TEXT trials which have changed care for premenopausal women with hormone receptor-positive early breast cancer. The DFCI-led ICECaP Working Group investigated surrogate endpoints of overall survival for localized prostate cancer trials and received the American Statistical Association’s 2021 SPAIG Award. She and colleagues proposed a treatment-free survival endpoint to measure durable remission arising from immunotherapy.
Dr. Regan is integral to statistical collaboration and faculty development at DFCI. She is a dedicated mentor to our biostatisticians and early career colleagues. She also serves as co-director of the DFCI Methods in Clinical Cancer Research prerequisite for all clinical trial PIs and sits on the Executive Committee for Clinical Research and Committee for Women Faculty (including 4 years as chair).
Nationally and internationally, Dr. Regan’s leadership in developing and interpreting breast cancer clinical trials to improve patient care includes US NCI Breast Cancer and EBCTCG Steering Committees, ASCO and ESMO clinical guidelines committees, and St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. She is a frequent reviewer for ASCO, grants and clinical oncology journals; associate editor for JNCI Cancer Spectrum; a Breast Cancer Research Foundation (BCRF) sponsored researcher and Fellow of the American Society of Clinical Oncology.